News
ICViewExpert PerspectivesMedical World NewsVideosWebinars
Conference
Infection Control TodaySupplements And Featured Publications
CME/CEJob BoardPartnersSponsoredWhitepapers
Print SubscriptioneNewsletter
Educator of the Year Nomination FormEducator of the Year Official RulesEducator of the Year
Advanced Technology
Bug of the Month
COVID-19
Environmental Services
HAIs
Hand Hygiene
Long-Term Care
Operating Room
Personal Protective EquipmentPersonal Protective Equipment
Prevention
Sterile Processing
Surface Disinfection
Vascular Access
Spotlight -
  • Expert Perspectives on Personal Protection Guidelines and Standardization Practices
  • Bug of the Month
Advanced Technology
Bug of the Month
COVID-19
Environmental Services
HAIs
Hand Hygiene
Long-Term Care
Operating Room
Personal Protective EquipmentPersonal Protective Equipment
Prevention
Sterile Processing
Surface Disinfection
Vascular Access
    • News
    • Conference
Advertisement

Coat of Proteins Makes Viruses More Infectious and Links Them to Alzheimer's Disease

May 28, 2019
Article

New research from Stockholm University and Karolinska Institutet shows that viruses interact with proteins in the biological fluids of their host which results in a layer of proteins on the viral surface. This coat of proteins makes the virus more infectious and facilitates the formation of plaques characteristic of neurodegenerative diseases such as Alzheimer's disease.

Are viruses dead or alive? Well... both. Viruses can only reproduce inside living cells and exploit the cellular machinery of their host to their benefit. However, before entering a host cell, viruses are just nanometer-sized particles, very similar to artificial nanoparticles used in medical applications for diagnosis and therapy. Scientists from Stockholm University and Karolinska Institutet have found that viruses and nanoparticles share another important property; they both become covered by a layer of proteins when they encounter the biological fluids of their host before they find their target cell. This layer of proteins on the surface influence their biological activity significantly.

"Imagine a tennis ball falling into a bowl of milk and cereals. The ball is immediately covered by the sticky particles in the mix and they remain on the ball when you take it out of the bowl. The same thing happens when a virus gets in contact with blood or lung fluids that contain thousands of proteins. Many of these proteins immediately stick to the viral surface forming a so-called protein corona," says Kariem Ezzat of Stockholm University and Karolinska Institutet.

Ezzat and his colleagues studied the protein corona of respiratory syncytial virus (RSV) in different biological fluids. RSV is the most common cause of acute lower respiratory tract infections in young children worldwide, leading up to 34 million cases and 196,000 fatalities each year. "The protein corona signature of RSV in the blood is very different from that in lung fluids. It is also different between humans and other species such as rhesus macaque monkeys, which also can be infected with RSV," Ezzat says. "The virus remains unchanged on the genetic level. It just acquires different identities by accumulating different protein coronae on its surface depending on its environment. This makes it possible for the virus to use extracellular host factors for its benefit, and we've shown that many of these different coronae make RSV more infectious."

The researchers from Stockholm University and Karolinska Institutet have also found that viruses such as RSV and herpes simplex virus type 1 (HSV-1) can bind a special class of proteins called amyloid proteins. Amyloid proteins aggregate into plaques that play a part in Alzheimer's disease where they lead to neuronal cell death. The mechanism behind the connection between viruses and amyloid plaques has been hard to find until now, but Kariem Ezzat and his colleagues found that HSV-1 is able to accelerate the transformation of soluble amyloid proteins into thread-like structures that constitute the amyloid plaques. In animal models of Alzheimer's disease, they saw that mice developed the disease within 48 hours of infection in the brain. In absence of an HSV-1 infection the process normally takes several months.

"The novel mechanisms described in our paper can have an impact not only on understanding new factors determining how infectious a virus is, but also on devising new ways to design vaccines. In addition, describing a physical mechanism that links viral and amyloid causes of disease adds weight to the increasing research interest in the role of microbes in neurodegenerative disorders such as Alzheimer's disease and opens up new avenues for treatments," Ezzat says.

Source: Stockholm University

Related Videos
Medical investigators going over data. (AdobeStock 589197902 by Wasan)
CDC logo is seen on a laptop. (Adobe Stock 428450603 by monticellllo)
Association for the Health Care Environment (Logo used with permission)
Ambassador Deborah Birx, , speaks with Infection Control Today about masks in schools and the newest variant.
mRNA technology  (Adobe Stock 485886181 by kaptn)
Ambassador Deborah Birx, MD
Woman lying in hospital bed (Adobe Stock, unknown)
Photo of a model operating room. (Photo courtesy of Indigo-Clean and Kenall Manufacturing)
GIANTmicrobes at the 2023 APIC Annual Conference and Exhibition.  (Photo by the author)
Related Content

Weekly Rounds: Data-Driven Action Against COVID-19, Emerging Pathogens, HIV Vaccine Trials Begin, and More

September 22nd 2023

NIH Announces HIV Vaccine Clinical Trial Begins

September 20th 2023

Organized Disinformation Fanning the COVID-19 Flames of Vaccine Hesitancy  

September 18th 2023

Hot Topics in IPC: COVID-19 Updated Booster, Legionella Infections, and Hospital Leadership

September 18th 2023

Protecting HCWs: Plague Doctor's Masks to the Personal Protective Equipment of Tomorrow

September 15th 2023

AHE Exchange Conference & Solution Center 2023 Review

September 14th 2023

Weekly Rounds: Data-Driven Action Against COVID-19, Emerging Pathogens, HIV Vaccine Trials Begin, and More

September 22nd 2023

NIH Announces HIV Vaccine Clinical Trial Begins

September 20th 2023

Organized Disinformation Fanning the COVID-19 Flames of Vaccine Hesitancy  

September 18th 2023

Hot Topics in IPC: COVID-19 Updated Booster, Legionella Infections, and Hospital Leadership

September 18th 2023

Protecting HCWs: Plague Doctor's Masks to the Personal Protective Equipment of Tomorrow

September 15th 2023

AHE Exchange Conference & Solution Center 2023 Review

September 14th 2023

Weekly Rounds: Data-Driven Action Against COVID-19, Emerging Pathogens, HIV Vaccine Trials Begin, and More

September 22nd 2023

NIH Announces HIV Vaccine Clinical Trial Begins

September 20th 2023

Organized Disinformation Fanning the COVID-19 Flames of Vaccine Hesitancy  

September 18th 2023

Hot Topics in IPC: COVID-19 Updated Booster, Legionella Infections, and Hospital Leadership

September 18th 2023

Protecting HCWs: Plague Doctor's Masks to the Personal Protective Equipment of Tomorrow

September 15th 2023

AHE Exchange Conference & Solution Center 2023 Review

September 14th 2023
Related Content
Advertisement

weekly rounds with infection control today

Weekly Rounds: Data-Driven Action Against COVID-19, Emerging Pathogens, HIV Vaccine Trials Begin, and More

September 22nd 2023
Article

Take 5 minutes to catch up on Infection Control Today®’s highlights for the week ending September 24, 2023.


NIH Announces HIV Vaccine Clinical Trial Begins

NIH Announces HIV Vaccine Clinical Trial Begins

September 20th 2023
Article

A new preventative vaccine has been developed incorporating technology funded by the NIH since 2004. The trials will be conducted in the United States and South Africa.


Vial of COVID-19 vaccine, bottle for injection with syringe.  (Adobe Stock 331786954 by myskin)

Organized Disinformation Fanning the COVID-19 Flames of Vaccine Hesitancy  

September 18th 2023
Article

Randomized controlled trials show masks are effective. With COVID-19, even one mistake in protective gear usage could lead to infection and obscure results.


In this Hot Topics in IPC, Saskia v. Popescu, PhD, MPH, MA, CIC, FAPIC, discusses COVID-19 vaccines and boosters, Legionella infections from transplants, and hospital leadership.

Hot Topics in IPC: COVID-19 Updated Booster, Legionella Infections, and Hospital Leadership

September 18th 2023
Article

In this Hot Topics in IPC, Saskia v. Popescu, PhD, MPH, MA, CIC, FAPIC, discusses COVID-19 vaccines and boosters, Legionella infections from transplants, and hospital leadership.


Plague doctor, a physician who treated bubonic plague.  (Adobe Stock FILE #: 559266031 by Worldillustrator)

Protecting HCWs: Plague Doctor's Masks to the Personal Protective Equipment of Tomorrow

September 15th 2023
Article

Plague doctors' historical attire was an early form of PPE. While modern PPE has improved, the quest for better, more comfortable protection continues as we aim for a future where health care workers can provide care confidently.


AHE: Association for the Health Care Environment  (Photo used with permission by AHE)

AHE Exchange Conference & Solution Center 2023 Review

September 14th 2023
Article

Health care environmental professionals met in Dallas, Texas, from July 31 to August 2, 2023, at the AHE Exchange Conference & Solution Center. Infection Control Today® asked Rock Jensen, AHE advisory board chair and administrative director of support services for Yuma Regional Medical Center in Arizona, about AHE’s areas of emphasis for leadership in environmental services (EVS).

Advertise
About Us
Editorial Board
Contact Us
Job Board
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News